News

Frost & Sullivan’s 2026 Global Company of the Year

12 May 2026

Frost & Sullivan’s 2026 Global Company of the Year

Frost & Sullivan is pleased to announce that Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology contract research organization (CRO) industry for its outstanding achievements in innovation, strategy execution, and customer impact.

  • Reset
Avance Clinical Partners with China Medical University Hospital in Taiwan to Strengthen Early-to-Late Phase Clinical Trial Pathway

20 March 2025

Avance Clinical Partners with China Medical University Hospital in Taiwan to Strengthen Early-to-Late Phase Clinical Trial Pathway

CMUH is renowned for its excellence in conducting clinical trials, and Avance Clinical specializes in early-phase clinical researchers.

Avance Clinical Signs Memorandum of Understanding with Taichung Veterans General Hospital, Expanding Trial Site Network in Taiwan

20 March 2025

Avance Clinical Signs Memorandum of Understanding with Taichung Veterans General Hospital, Expanding Trial Site Network in Taiwan

Avance Clinical signed a Memorandum of Understanding (MOU) with Taichung Veterans General Hospital (TCVGH), one of Taiwan’s leading medical centers with extensive clinical trial expertise.

Avance Clinical and Taipei Medical University Join Forces to Accelerate Clinical Research and Biotech Innovation in Asia

19 March 2025

Avance Clinical and Taipei Medical University Join Forces to Accelerate Clinical Research and Biotech Innovation in Asia

Avance Clinical as signed a Memorandum of Understanding (MOU) with Taipei Medical University (TMU), one of Taiwan’s leading medical institutions with extensive clinical trial expertise.

Avance Clinical Expands in Asia with Taipei Office to Accelerate Biotech Clinical Trials

18 March 2025

Avance Clinical Expands in Asia with Taipei Office to Accelerate Biotech Clinical Trials

Avance Clinical has further strengthened its presence in Asia with the opening of an office in Taipei, Taiwan.

Global Reach for Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites

17 March 2025

Global Reach for Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites

Avance Clinical is pleased to announce the signing of four Memorandums of Understanding (MOUs) with key clinical trial sites in Taiwan this week.

Simbec-Orion and Avance Clinical Consolidates Partnership with Memorandum of Understanding

25 February 2025

Simbec-Orion and Avance Clinical Consolidates Partnership with Memorandum of Understanding

Simbec-Orion and Avance Clinical are thrilled to announce the signing of a Memorandum of Understanding (MOU), marking a significant milestone in their strategic partnership.

Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia

13 January 2025

Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia

Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce it is the CRO of choice for early phase clinical trials in Australia.

Avance Clinical Bolsters Asia-Pacific Presence with Strategic Partnerships in South Korea

9 December 2024

Avance Clinical Bolsters Asia-Pacific Presence with Strategic Partnerships in South Korea

Avance Clinical’s CEO Yvonne Lungershausen and Asia Regional Director Jessica Han represented the company at KoNECT, formalizing partnerships with CHA University Bundang Medical Center, Korea University Medicine, and Dong-A University Hospital.

Avance Clinical teams with trial sites in Korea

9 December 2024

Avance Clinical teams with trial sites in Korea

Avance Clinical has signed deals with three clinical trial sites in Korea, citing a desire to expand its local presence.

Avance Clinical’s CEO Yvonne Lungershausen on Expanding Footprint in Asia-Pacific: A Strategic Focus on South Korea’s Clinical Excellence

7 December 2024

Avance Clinical’s CEO Yvonne Lungershausen on Expanding Footprint in Asia-Pacific: A Strategic Focus on South Korea’s Clinical Excellence

In a recent conversation with Ankit Kankar from BioSpectrum Asia, Yvonne Lungershausen, CEO of Avance Clinical, shared insights into the company’s latest strategic moves in the Asia-Pacific region.

The CEO Magazine – Yvonne Lungershausen

20 November 2024

The CEO Magazine – Yvonne Lungershausen

Under CEO Yvonne Lungershausen’s leadership, Avance Clinical has achieved an exceptional client retention rate, expanded its global biotech client portfolio and boosted revenue by over 500 percent. With a strong focus on innovative, technology-driven research solutions, the company has broadened its international footprint, advancing its mission to deliver improved patient outcomes worldwide.

Avance Clinical Recognized as Finalist in 62nd Australian Export Awards for International Health

18 November 2024

Avance Clinical Recognized as Finalist in 62nd Australian Export Awards for International Health

Avance Clinical, a leading Australian Contract Research Organization (CRO), has been named a finalist in the prestigious 62nd Australian Export Awards, under the International Health category.

Proven industry
experience & expertise

500+

Studies in the past 5 years

450+

Experienced team members

18k+

Participants past 5 years

30

Years of CRO experience